![Joanna Smith](https://profiles-cardiff.imgix.net/attachments/3649?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Joanna Smith
Research Associate - Trial Manager
- Available for postgraduate supervision
Overview
I have a track record of research in clinical trials, diagnostic development, genetics and microbiology and, in particular, have built a reputation for excellence in clinical trial methodology through the development and project management of multiple CTIMP and non-CTIMP clinical trials in the solid tumour and haematological oncology and infections clinical settings.
Publication
2023
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
2015
- Noble, S. I. et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19(83), pp. 1-94. (10.3310/hta19830)
- Geldart, T. et al. 2015. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67(4), pp. 599-602. (10.1016/j.eururo.2014.11.003)
2014
- Noble, S. et al. 2014. ALICAT: Anticoagulation length in cancer associated thrombosis - a mixed-methods feasibility study. Thrombosis Research 133(Supp 2), pp. S220-S220. (10.1016/S0049-3848(14)50032-1)
- Smith, J. D. et al. 2014. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study. Trials 15(1), article number: 122. (10.1186/1745-6215-15-122)
Articles
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
- Kitson, T. et al. 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13(9), article number: e073049. (10.1136/bmjopen-2023-073049)
- Noble, S. I. et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19(83), pp. 1-94. (10.3310/hta19830)
- Geldart, T. et al. 2015. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67(4), pp. 599-602. (10.1016/j.eururo.2014.11.003)
- Noble, S. et al. 2014. ALICAT: Anticoagulation length in cancer associated thrombosis - a mixed-methods feasibility study. Thrombosis Research 133(Supp 2), pp. S220-S220. (10.1016/S0049-3848(14)50032-1)
- Smith, J. D. et al. 2014. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study. Trials 15(1), article number: 122. (10.1186/1745-6215-15-122)
Research
My research interests are cross cutting within the cancer and infections, inflammation and immunity (I3) division themes of the Centre of Trials Research, and include cancer and cancer treatment complications, survivorship and end of life, microbiological infections, microbial drug resistance, genitourinary tract infections, and clinical diagnostics with a specific focus on point-of-care. I am the CTR genitourinary tract I3 sub-theme lead.
My main current active study is: ADVANCE: Community based point of care white cell count testing to improve pathways for cancer patients with neutropenic sepsis or borderline neutropenia whilst receiving chemotherapy. POCT - Centre for Trials Research - Cardiff University
I recently supported set up of the CONSCOP2 clincial trial: A randomised controlled trial of contrast enhanced colonoscopy in the reduction of right sided bowel cancer. CONSCOP2 - Centre for Trials Research - Cardiff University
I have supported numerous solid tumour and haematological drugs and surgery treatment cancer trials, often with embedded biological sample collection or qualitative components, including: FURVA, FAKTION, ALICAT, SUCCINCT, TOTEM, BOLERO, TOUCAN, FRAGMATIC, T-FRAG, CEBOC, COPELIA, AML15, AML16, AML17, and MONOCLE. Studies and trials - Centre for Trials Research - Cardiff University
I am curently involved in the development of new research projects in the areas of end-of-life pressure ulcer care related decision making in primary care, better dietary and exercise preparedness of patients for cancer treatment, anti-helminth (threadworm) incidence, prevalence and drug resistance, the use of Apps, other digital technologies, diagnostic tools and medical devices to support better diagnosis and managment of cancer and infections.
Biography
Education and qualifications:
- 1997: PhD Biological Sciences, University of Warwick, UK
- 1993: MSc (Distinction) Molecular Genetics, Leicester University, UK
- 1992: BSc(Hons) Microbiology, Kent University, UK
Career overview:
- 2008 - present: Trial Manager/Research Associate, Centre for Clinical Trials (CTR; previously known as Wales Cancer Trials Unit (WTU)), Cardif University, UK
- 2020. Temporary Senior Trial Manager/Research Fellow, Centre for Trials Research (CTR), Cardiff University, UK
- 2019. Temporary Senior Trial Manager/Research Fellow, Centre for Trials Research (CTR), Cardiff University, UK
- 2013: Temporary Senior Trial Manager/Research Fellow, Wales Cancer Trials Unit (WCTU), Cardif University, UK
- 2003 - 2007: Project Leader, R&D, BBInternational Diagnostics, Cardiff, UK
- 2000 - 2003: Senior Research Scientist / Project Leader, Nucleic Acid Division, Cytocell Ltd, Coventry, UK
- 2000: Post Doctoral Reseach Assistant, Molecular Cell Biology, Warwick University, UK
- 1998 - 2000: Post Doctoral Reseach Assistant, Molecular Bacterial Ecology, Warwick University, UK
- 1997 - 1998: Post Doctoral Reseach Assistant, Department of Genetics, Cambridge University, UK
- 1990 - 1991: Industrial Trainee, Pfizer Central Research, Sandwich, Kent, UK
- 1990: Medical Laboratory Assistant, Rugby Hospital, Warwickshire, UK
- 1989: Medical Laboratory Assistant, Rugby Hospital, Warwickshire, UK
Professional memberships
- Member of the Trial Managers Network (TMN)
Academic positions
- 2000: Post Doctoral Reseach Assistant, Molecular Cell Biology, Warwick University, UK
- 1998 - 2000: Post Doctoral Reseach Assistant, Molecular Bacterial Ecology, Warwick University, UK
- 1997 - 2000: Post Doctoral Reseach Assistant, Department of Genetics, Cambridge University, UK
Supervisions
I am interested in supervising PhD students in the areas of:
- Clinical trials
- Cancer and cancer treatment and survivorship complications
- End-of-life care related decsion making in primary care
- Genitourinary tract infections
- Antihleminth incidence, prevalence and drug resistance
- Diagnostic tools and medical devices
Contact Details
+44 29206 87904
Neuadd Meirionnydd, Room 6th Floor, University Hospital of Wales, Heath Park, Cardiff, CF14 4YS